Related Experiment Video
Updated: Dec 29, 2025
CRISPR/Cas9 Gene Editing of Hematopoietic Stem and Progenitor Cells for Gene Therapy Applications
Published on: August 9, 2022
Novel Therapies in Polycythemia Vera
Douglas Tremblay1, John Mascarenhas2
1Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1079, New York, NY, 10029, USA.
New treatments for polycythemia vera (PV) are emerging. These novel therapies aim to reduce clotting and directly target the malignant cells, potentially altering disease progression.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Polycythemia vera (PV) is a myeloproliferative neoplasm.
- Characterized by elevated erythrocyte count and increased thrombotic risk.
- Current treatments like hydroxyurea, pegylated interferon alfa-2a, and ruxolitinib have limitations.
Purpose of the Study:
- To review current therapeutic options for PV.
- To detail novel agents in clinical development for PV.
- To discuss the expanding therapeutic landscape for PV patients.
Main Methods:
- Review of existing literature on PV treatments.
- Analysis of clinical trial data for investigational therapies.
- Synthesis of information on novel agents targeting PV.
Main Results:
- Current therapies for PV include hydroxyurea, pegylated interferon alfa-2a, and ruxolitinib.
- Novel agents such as MDM2 inhibitors, histone deacetylase inhibitors, and long-acting pegylated interferon alfa-2b show promising efficacy.
- These new agents aim to reduce thrombotic potential and target the malignant PV clone.
Conclusions:
- The therapeutic options for PV are expanding.
- Novel investigational therapies offer potential for improved disease modification.
- Future treatments may offer better efficacy and safety profiles for PV patients.
More Related Videos
05:23Continuous Manual Exchange Transfusion for Patients with Sickle Cell Disease: An Efficient Method to Avoid Iron Overload
Published on: March 14, 2017
07:24A Precision Medicine Tool for Measurement and Monitoring of Hemoglobin S in Sickle Cell Disease Patients Receiving Transfusion Therapy
Related Concept Videos
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:16Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:14Erythropoiesis